These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29200035)

  • 1. Meningococcal Disease: Vaccines-Who's at Risk and the Future.
    O'Malley PA
    Clin Nurse Spec; 2018; 32(1):15-18. PubMed ID: 29200035
    [No Abstract]   [Full Text] [Related]  

  • 2. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.
    Rose WE
    J Am Pharm Assoc (2003); 2014; 54(2):198-201. PubMed ID: 24632933
    [No Abstract]   [Full Text] [Related]  

  • 3. Meningococcal disease: Can we predict the unpredictable?
    Martinón-Torres F; Trilla A
    Med Clin (Barc); 2020 Jan; 154(1):20-22. PubMed ID: 31350058
    [No Abstract]   [Full Text] [Related]  

  • 4. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and meningococcal serogroup distribution in the United States.
    Hershey JH; Hitchcock W
    Clin Pediatr (Phila); 2010 Jun; 49(6):519-24. PubMed ID: 20507868
    [No Abstract]   [Full Text] [Related]  

  • 10. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.
    Macneil JR; Cohn AC; Zell ER; Schmink S; Miller E; Clark T; Messonnier NE;
    Pediatr Infect Dis J; 2011 Jun; 30(6):451-5. PubMed ID: 21206392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
    MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW
    MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease.
    Marshall GS; Dempsey AF; Srivastava A; Isturiz RE
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):244-247. PubMed ID: 31077326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal vaccine for infants?
    Campos-Outcalt D
    J Fam Pract; 2012 Aug; 61(8):482-4. PubMed ID: 22871657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
    Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.